(Q35587289)

9 August 2017

1 reference

title

Temozolomide: realizing the promise and potential (English)

1 reference

9 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

3 April 2024

author name string

R. Nagasubramanian

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624222

3 April 2024

M. Eileen Dolan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624222

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14624222

3 April 2024

publication date

1 November 2003

1 reference

full work available at URL

9 August 2017

https://journals.lww.com/00001622-200311000-00002

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Current Opinion in Oncology

3 April 2024

published in

1 reference

9 August 2017

volume

15

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

412-418

1 reference

9 August 2017

cites work

Cancer statistics, 2000.

1

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Mismatch repair in replication fidelity, genetic recombination, and cancer biology

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents.

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Phase II trial of temozolomide in patients with progressive low-grade glioma

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

3 April 2024

32

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Phase II evaluation of temozolomide in metastatic choroidal melanoma

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system

3 April 2024

42

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

3 April 2024

45

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents

3 April 2024

46

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

3 April 2024

48

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system

3 April 2024

50

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

3 April 2024

52

1 reference

https://api.crossref.org/works/10.1097/00001622-200311000-00002

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference